Page 458 - Feline Cardiology

Index 483

Himalayan cats life-threatening, treatment of, 312t systemic hypertension and, 331, 332,
HCM in, 118 mild, 246 334
PPDH and, 343 moderate to severe, 246 thyroid storm, 401
Histopathologic myocardial lesions, in PVCs vs., 232 treatment, 403–404
cats with HCM, 111 sinus bradycardia and, 246 antithyroid therapy, 403–404
History taking, 5 in two male cats with urethral cardiovascular drugs, 404
HOCM. See Hypertrophic obstructive obstruction, 248 ventricular tachcardia and, 234
cardiomyopathy in 2-year-old male domestic short- Hypertrophic cardiomyopathy (HCM), 9,
Hollow treats, managing coexisting haired cat with urethral 103–175, 257
cardiac and renal problems obstruction, 247 adult onset of, 426
with, 371–372 very high serum potassium advanced cardiovascular testing for,
Holter monitoring, electrocardiography concentrations and, 246–247 overview, 142
and, 80–81, 81 Hypertension. See also Systemic with alveolar pulmonary pattern
Homocysteine, blood levels and, 69 hypertension consistent with severe
Homozygous, 425 arterial blood pressure and, 281–282 congestive heart failure, 43
Homozygous cats, genetic screening for heart failure and, 270 lateral and ventrodorsal views of cat
HCM in, 428 or hypertension-associated abnormality, with, 45
Hospitalized cats with HCM, treatment incidental finding of, 332 anesthetic management and, 413, 415
of, 162–165, 290–293 primary or “essential,” 330 arterial thromboembolism and, 305
HR (bpm), 60t systemic, secondary concentric assays and, 71–72
Humans hypertrophy and, 120–121 azotemia and, 368
etiology of HCM in, 106–109 Hypertensive choroidopathy, retinal cardiac magnetic resonance imaging
premature ventricular complexes in, detachment as consequence of and, 142–147
229 subretinal fluid accumulation delayed enhancement, in cats with
sinus node dysfunction in, 243 related to, 328 HCM, 146
HWD. See Heartworm disease Hypertensive crisis, 338 diastolic function assessed by,
Hydralazine, 443 Hyperthyroid heart disease, 395 146–147
hypertensive crisis and, 338 Hyperthyroidism, 395–404 for left ventricular mass
indications, dosage, available sizes, 451 apathetic, 400 quantification, 144–145
Hydrochlorothiazide arterial thromboembolism and, 309 myocardial fibrosis assessed with,
coexisting cardiac and renal problems cardiovascular pathologic findings of, 145–146
and, 372 399 technique, in cats, 143–144
congestive heart failure and, 435 causes of, 398–399 characteristics of, 117–118
medical therapy and monitoring of concentric ventricular hypertrophy due coagulation markers, 151
cats with, 285t to, anesthesia and, 415 compensated, sinus tachycardia in
refractory, 293, 294 concurrent thyrotoxic heart disease and anxious cat with, 218
indications, dosage, available sizes, 451 HCM, 399 complications and monitoring,
HydroDiuril (hydrochlorothiazide), 451 congestive heart failure and, 270 165–167
Hydromorphone, anesthesia, for cardiac diagnostic testing, 401–403 monitoring asymptomatic cat,
patient, 414t, 417 advanced testing, 403 166–167
Hydrothorax, heartworm disease and, 355 initial tests, 401–403 monitoring symptomatic cat with
Hyperadrenocorticism, 405 differential diagnosis and variants, HCM and heart failure, 167
Hyperaldosteronism, 405–406 400–401 congestive heart failure due to, 258–259
cause of, 405 etiology, pathophysiology, and gross continuous-wave Doppler
systemic hypertension and, 333, 334 pathology, 396–398 echocardiography in cat with
treatment, 406 HCM and, 120 severe SAM of the mitral valve
Hypercalcemia, cardiac effects with, 249 history and chief complaint, 399–400 and, 136
Hypercoagulability mechanism of, 396 defined, 104
HCM and, 151 outcome and prognosis, 404 delayed enhancement cMRI in cats
heart disease and, 306 physical examination, 400 with, 146
Hyperglobulinemia, heartworm disease premature ventricular complexes and, diagnosis of, 426–427
and, 359 229 diagnostic testing, 122–152
Hyperglycemia, arterial prevalence of cardiovascular electrocardiogram, 123–125
thromboembolism and, 309 abnormalities with, 395–396 general diagnostic tests, 122–123
Hyperinsulinemia, heart failure and, 270 prevalence of systemic hypertension genetic testing for, 425–428
Hyperkalemia and, 328–329 overview, 122
arterial thromboembolism and, secondary concentric left ventricular thoracic radiographs, 125–126
311–312 hypertrophy and, 120 diastolic dysfunction, 112–118
cardiac effects with, 245–248 signalment, 399 arterial thromboembolism, 116–117
intravenous calcium infusions and, 248 syncope and, 15 congestive heart failure, 115–116